News Daily News Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression L.A. McKeown February 17, 2023
News Daily News Food Insecurity May Drive Heart Failure, CAD Risks in Black Individuals L.A. McKeown February 06, 2023
News Daily News Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS Michael O'Riordan December 30, 2022
News Daily News Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths Michael O'Riordan December 08, 2022
News Daily News Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use L.A. McKeown October 05, 2022
News Daily News Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive Michael O'Riordan September 09, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Conference News ESC Heart Failure 2022 Dapagliflozin Boosts Health Status Across LVEF Range Shelley Wood May 23, 2022
News Daily News FDA Approves Empagliflozin for Treatment of HFpEF Michael O'Riordan February 24, 2022
News Opinion Editor's Corner AHA 2021 AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More Shelley Wood November 08, 2021
News Daily News HFSA 2021 In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity Michael O'Riordan September 15, 2021
News Daily News Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results Todd Neale July 06, 2021
News Daily News Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care Shelley Wood May 27, 2021
News Conference News ACC 2021 Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF Yael L. Maxwell May 16, 2021
News Daily News Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA Michael O'Riordan April 26, 2021
News Conference News AHA 2020 Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials Michael O'Riordan November 17, 2020
News Daily News Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors Shelley Wood September 30, 2020
News Daily News VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks Michael O'Riordan September 24, 2020
News Conference News ESC 2020 EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF Michael O'Riordan August 28, 2020